Article

Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccination

2022-07-18

Abstract excerpt

A large proportion of the global population received a single dose of the Ad26.COV2.S coronavirus disease-2019 (COVID-19) vaccine as priming vaccination, which was shown to provide protection against moderate to severe COVID-19. However, the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants that harbor immune-evasive mutations in the spike protein led to the recommendation of boost...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6cde79ac-c82b-531c-ba0c-800961dc7a3b
DOI: 10.1101/2022.07.15.22277639

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccinationDOI 10.1101/2022.07.15.22277639Read

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S PrimingSemantic proximity Read

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipientsSemantic proximity Read

Evaluation of bivalent Omicron BA.1 booster vaccination after different priming regimens in healthcare workers (SWITCH ON): a randomized controlled trialSemantic proximity Read

Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity Read

Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccinationSemantic proximity Read

Sustained Humoral Activation through self-amplifying mRNA Vaccination Enhances Longitudinal Antibody Function in a Phase III TrialSemantic proximity Read

Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccinationSemantic proximity Read

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.SSemantic proximity Read

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccinesSemantic proximity Read

Serum anti-Spike antibody titers before and after heterologous booster with mRNA-1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccineSemantic proximity Read

Profiling antibody epitopes induced by mRNA-1273 vaccination and boostersSemantic proximity Read